CSPAX | LLGLX | CSPAX / LLGLX | |
Total Expense Ratio | 1.06 | 1.05 | 101% |
Annual Report Gross Expense Ratio | 1.06 | 1.29 | 82% |
Fund Existence | 24 years | 13 years | - |
Gain YTD | 9.650 | 11.787 | 82% |
Front Load | 4% | N/A | - |
Min. Initial Investment | 250 | 10000 | 3% |
Min. Initial Investment IRA | N/A | N/A | - |
Net Assets | 80.3B | 259M | 31,004% |
Annual Yield % from dividends | 0.58 | 2.92 | 20% |
Returns for 1 year | 10.22 | 14.18 | 72% |
Returns for 3 years | 21.60 | 32.12 | 67% |
Returns for 5 years | 14.95 | 26.21 | 57% |
Returns for 10 years | 50.82 | 48.27 | 105% |
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
FPHAX | 24.89 | 0.35 | +1.43% |
Fidelity Select Pharmaceuticals Port | |||
ETCEX | 12.80 | N/A | N/A |
Eventide Exponential Technologies C | |||
QILGX | 41.30 | N/A | N/A |
Federated Hermes MDT Large Cap Growth IS | |||
OIEIX | 25.09 | -0.07 | -0.28% |
JPMorgan Equity Income A | |||
LSRCX | 1.85 | -0.02 | -1.07% |
Lord Abbett Small Cap Value C |